VANCOUVER, BC – TheNewswire - August 11, 2022 – Izotropic Corporation ("Izotropic" or the "Company") (CSE:IZO) (OTC:IZOZF) (FSE:1R3), a MedTech company commercializing IzoView, an advanced three-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer, is pleased to report the Company has successfully relocated IzoView and associated components and completed the transition of all major medical device engineering and product development operations to California.
Further to the Company's prior announcement, the move to relocate commercial development of IzoView to Sacramento, CA was made to help accelerate testing and optimization of the device as the Company prepares for its upcoming clinical study and submission for market authorization in the U.S.
The technical team, led by Executive Vice President of Product Engineering Dr. Younes Achkire, has been testing and calibrating all transferred components of IzoView onsite while actively pursuing measures to simplify and streamline the design.
"The decision to transition IzoView R&D and supply chain efforts to California now creates an environment for frequent, in-person access to key medical, technical, and manufacturing partners while better managing supply chain dynamics and operational oversight," said Dr. John McGraw, CEO. "Additional benefits include mitigation of cross-border travel and critical component delivery risks and the opportunity for greater interaction with our industry peers at US-based hospitals and clinics."
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
ON BEHALF OF THE BOARD
John McGraw, CEO
Investor Relations Contact:
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Toll Free: 1-833-IZOCORP ext.3
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible,
to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.